Home > Boards > US OTC > Electronics and components > G6 Materials Corp. (GPHBF)

From Company e-mail

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
LUKEYE Member Profile
 
Followed By 1
Posts 87
Boards Moderated 0
Alias Born 03/22/20
160x600 placeholder
LUKEYE   Tuesday, 09/01/20 10:21:06 PM
Re: None
Post # of 486 
From Company e-mail

Antiviral Products: The Company secured the IP rights by filing Provisional Patent Application #63/021,996, entitled “Antiviral Graphene Oxide Air Filtration Device and Associated Methods”, with the USPTO on June 26, 2020. This patent application covers G6’s proprietary formulation of a graphene-oxide antiviral coating for HEPA air filters. The Company plans to use this technology to make air filtration products that help mitigate the outbreak of infectious viruses, with the plan to commercialize such products currently being developed by management.

Graphene Energy Storage: The USPTO recently granted G6 patent No. 10,727,537 entitled “Electrochemical Devices Comprising Nanoscopic Carbon Materials Made by Additive Manufacturing”. This patent covers a technology developed by the Company to formulate 3D printing materials that are suitable to make functional electrical energy storage devices.

Multisegmented 3D Printing Filament: Patent No. 10,611,098 was granted to G6 by the USPTO on April 7, 2020 and is entitled “Fused Filament Fabrication Using Multi-Segment Filament”. The patent covers the Company’s invention of a 3D printing filament comprised of multiple segments that enables the use of commercially available 3D printers to fabricate complex structures made of a variety of materials. This technology is useful in making functional devices that are meant to be operational immediately after being 3D printed, for example, electrochemical storage devices.

Method of TFK Production. Patent No. 10,472,313 was recently granted by the USPTO and is entitled the “Process for Synthesizing of Trifluoroketones”. The technology covered by this patent has been licensed by the Company to a pharmaceutical company that uses trifluoroketones to make an active drug ingredient that is currently under development.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences